RCS - Roquefort Theraptcs. - Investor Presentation

Roquefort TherapeuticsAnnouncement

21/03/2022 09:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220321:nRSU4336Fa&default-theme=true

RNS Number : 4336F  Roquefort Therapeutics PLC  21 March 2022

21 March 2022

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Investor Presentation

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company
focused on early-stage opportunities in the biotechnology sector, is pleased
to announce that Chairman Stephen West and Chief Scientific Officer Graham
Robertson will provide a live presentation giving an Introduction to the
Company via the Investor Meet Company platform on Friday, 25(th) March 2022 at
9am GMT.

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and can arrange to
meet ROQUEFORT THERAPEUTICS via:

https://www.investormeetcompany.com/roquefort-therapeutics-plc/register-investor
(https://www.investormeetcompany.com/roquefort-therapeutics-plc/register-investor)

Investors who already follow ROQUEFORT THERAPEUTICS PLC on the Investor Meet
Company platform will automatically be invited.

ENDS

Enquiries:
 Roquefort Therapeutics plc
 Stephen West (Chairman)                    +44 (0)20 3290 9339

 Buchanan (Public Relations)

 Ben Romney / Jamie Hooper / George Beale   +44 (0)20 7466 5000

 Optiva Securities Limited (Broker)
 Christian Dennis                           +44 (0)20 3411 1881

 

For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com (http://www.roquefortplc.com) and @RoquefortTherap on
Twitter.

LEI: ‎254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company
developing products through the pre-clinical phase prior to partnering or
selling to big pharma.  The Company is focused on developing first in class
Midkine inhibiting RNA therapeutic drugs for the treatment of cancer, chronic
inflammatory, autoimmune disorder and COVID-19.  Recent progress within mRNA
therapeutics has led to a reduction in drug development timelines and costs,
increasing the chance of early value creation.

Through extensive research resulting in validation through publication in over
1,000 scientific publications, Roquefort Therapeutics has identified the
potential to exploit the broad therapeutic potential of Midkine for a number
of clinical indications of significant unmet need. Roquefort Therapeutics
holds the largest global IP portfolio on Midkine. The Midkine blocking drug
development markets have significant global market potential (in the
multi-billion dollars). Roquefort Therapeutics pre-clinical programme is
currently underway with an initial focus on cancer treatment aiming to improve
immunotherapy responses.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUAOKRUAUOURR